Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  166.00 1.57% 10,752.00 10,748.00 10,750.00 10,844.00 10,666.00 10,682.00 2,587,961 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,668.9 -196.0 5.9 1,620.0 166,561

Astrazeneca Share Discussion Threads

Showing 5751 to 5773 of 5875 messages
Chat Pages: 235  234  233  232  231  230  229  228  227  226  225  224  Older
DateSubjectAuthorDiscuss
12/10/2022
17:23
20 million deaths and 2 billion adverse events estimated from the jabs world wide .........so far !!

Https://rumble.com/v1ndh9e-20-million-dead-from-the-jab-2.2-billion-injured-analyst-estimates.html


Steve73 12 Oct '22 - 03:32 - 140076 of 140098

ref. the adverse reactions & deaths from the jabs.


"Our world in data" indicates that 68.2% of the global pop'n has had at least one vax (that's c. 5.5 Bn souls). It also indicates 12.8 Bn doses have been administered, which means the average number of shots per person is c. 2.3.

Assuming the estimated 2.2Bn adverse reactions is even close to correct, that's 40% of everyone jabbed. (of course, some people could have had more than one adverse reaction, so the number/% of people having adverse reactions is almost certainly much less than this.

The 20 Mn deaths represents around 0.37% (this represent the true number/% since people can only die once.!!). Worldometers website suggests Covid itself has caused only 6.5 Mn deaths (mostly among the elderly/co-morbid of course).

So it appears that the jab have caused mor than three times as many as died from covid itself.... and that's just so far. Many people jabbed are likely to die prematurely.

Going back to the "our world in data"..
84% of high income countries have been jabbed,
80% of upper middle income,
64% of lower middle income,
but just 23% of lower income countries.

If this doesn't tell you that the upper/middle income countries have been directly targeted for depopulation... and these are the sections of the population that consume "most" of the worlds energy/oil/resources.

Clearly, the low income populations are being preserved to "serve" the elite after the Great Reset has been completed.

links I've used:
htTps://ourworldindata.org/covid-vaccinations
htTps://www.worldometers.info/coronavirus/

jimarilo
12/10/2022
17:21
See this: Private business jets demanding unvaccinated pilots

hTTps://gettr.com/post/p1tyfv4ac4c

jimarilo
08/10/2022
06:19
Interesting comments if interested on AstraZeneca FYI:

htTps://www.ii.co.uk/analysis-commentary/stockwatch-fresh-opportunity-bet-ftse-100-defensive-stock-ii525556

mirandaj
07/10/2022
08:08
bought RENE (LSE) today
blackhorse23
06/10/2022
17:41
If there is a market fall AstraZ will fall along with everything else. I sold 20% of my holding at 114 ( I now wish I had been more decisive and sold more) and await a further dip before buying back in. The bond markets show how stressed the markets are. The odds look pretty strong on further falls to provide an opportunity to buy back before the month is out. I have a limit order in. I am happy to wait on the sidelines with cash in hand.

This has been a depressing year for investors, but it has at least provided numerous opportunities to reduce the capital committed to core holdings while maintaining or even increasing the number of shares held, and with shares paying dividends half yearly there is not even much risk of dropping a dividend.

1knocker
04/10/2022
06:10
AZN eyeing up Avacta!?!
lostabillion
02/10/2022
17:53
thanks for that; rech
bostonborn
02/10/2022
10:33
@ bostonborn

In Questor’s view, investors do not necessarily face a binary choice between safety and growth. Indeed, some companies, such as the FTSE 100 pharmaceutical company AstraZeneca, offer the best of both.

From a defensive standpoint, its recent half-year results highlight its financial strength amid an uncertain global economic outlook. Revenue and core profits grew by 48pc and 44pc respectively and all business units delivered an improved performance.

This led the company to raise its sales guidance for the full year: it now expects a percentage increase in the low 20s. A net‑debt‑;to‑equity ratio of 69pc further highlights its capacity to withstand the sharp monetary policy tightening that is taking place across the developed world.

The company’s improving financial performance allows it to invest greater sums in research and development. Core R&D spending in the first half of the year increased by 40pc and as a proportion of sales it is now 1 percentage point higher at 23pc than in the same period of the previous year. This should strengthen its product pipeline in an era when rising healthcare spending creates significant long-term growth opportunities.

The world’s population is rapidly growing and quickly ageing. Between now and 2050 the UN forecasts it to grow from eight billion people to 9.7 billion people.

Over the same period the number of people aged 65 or over is expected to almost double to 1.6 billion. With 71pc of worldwide deaths caused by non-communicable diseases such as cancer, cardiovascular disease and others that cannot be transmitted between people, demand for AstraZeneca’s oncology and biopharmaceutical products is likely to rise.

Last year’s acquisition of rare diseases specialist Alexion provides a further long-term growth opportunity. Currently, 400 million people are affected by a rare disease but only 5pc of the more than 7,000 rare diseases known to exist today have treatments.


Separately, AstraZeneca’s large presence in emerging markets, which account for 28pc of its revenues, makes it well placed to capitalise on their growth potential. In fact, according to the IMF they will grow almost three times faster than developed markets next year.

Of course, AstraZeneca is not immune from potential threats to its performance. Rumours persist that its chief executive, Pascal Soriot, is to leave in the near future. His eventual departure, after he led the company to a vast improvement in fortunes since he took over a decade ago, is almost certain to cause a degree of uncertainty, which is likely to be reflected in heightened share price volatility.

Similarly, the company’s outperformance of the wider stock market means it trades on a relatively rich valuation. It has gained 35pc and beaten the FTSE 100 by 41 percentage points since this column first advised readers to buy the stock in August 2019. As a result it now trades at around 17 times forecast earnings.

In Questor’s view, AstraZeneca is extremely worthy of its premium valuation. Its potent mix of defensive and growth characteristics is particularly attractive in the current economic environment.

Its exposure to emerging markets, its focus on non-communicable diseases that are likely to become more prevalent and its growing R&D spending mean it should remain a mainstay of investors’ portfolios. Buy

rech
02/10/2022
10:03
Today's Questor in the telegraph has AZN as a buy. Can someone please post the complete article.
It was tipped in the Times on Thursday or Friday. It may be a 'repeat' of this article. Summary of which was 'great pipeline of new drugs coming through over the next year or two, which should bring growth; also a 'safe' share'

bostonborn
26/9/2022
20:46
AZN Plc share going to match £115 price anytime soon over the next few weeks ??
sb34
26/9/2022
14:55
Danger is our best uk companies look cheap and will be taken over :-(
evianone
26/9/2022
07:15
Weak pound certainly boosting profits of FTSE 100 dollar earners.
montyhedge
19/9/2022
17:53
Investors wiped more than $10bn off the market value of the main Covid-19 vaccine makers on Monday after US president Joe Biden said “the pandemic is over”.

Shares in Moderna, BioNTech and Novavax fell as much as 9 per cent


https://www.ft.com/content/c6fcbde9-9575-4c9c-a6eb-2c8796c2c5cb

philanderer
16/9/2022
07:12
https://www.google.com/amp/s/capital.com/amp/cury-currys-share-price-double
blackhorse23
13/9/2022
15:34
ii I think best online broker, dividends in at 8am day of payment, plus they are cheap on commission.
montyhedge
13/9/2022
14:20
G, very impressed with ii too. And they've cut their trade charge now to £5.99p
philanderer
12/9/2022
06:57
Dividend paid into my account this morning. Interactive Investor are always very prompt with their dividend payments.
gateside
11/9/2022
20:58
Emphasizing the 'stark imbalance' between penalties and profits, the consumer group concluded that without more sincere and active enforcement - including prosecution and jail sentences for executives overseeing systemic fraud - 'illegal but profitable activities will continue to be part of [pharmaceutical] companies' business mode. hTTps://themadtruther.com/2022/09/11/pharmas-criminal-business-model-and-how-the-u-s-government-benefits-from-it/
aidenabettin
11/9/2022
20:09
hTTps://themadtruther.com/2022/07/31/politicians-saying-you-wont-get-covid-if-youre-vaxxed-hilarious-mashup/
aidenabettin
11/9/2022
17:32
You won't see it below 100 again.
hotfinance14
11/9/2022
17:16
I sold a third of my holding at 114, with a view to buying back lower. It just felt too expensive. I confess though that I find it difficult to fix on a target price to buy back. Under 100 for sure, but how much under? It seems reasonable to hope for 95, but I may settle for 97, as this is a long term holding.

I am personally very dubious about multiple vaccinations. I have had 3, the initial 2 and one top up, and am tempted to leave it at that. Various medical friends are equivocal too, but suggest that the AstraZeneca one is the version to go for if one is going to have more, as it is the least likely to do damage to one's natural immune system. I don't pretend to understand the science, so I shall not attempt to explain the reasoning!

1knocker
07/9/2022
11:16
Morgan Stanley cuts AstraZeneca to 'equal-weight' (overweight)
philanderer
07/9/2022
08:43
Bad few weeks continues.
philanderer
Chat Pages: 235  234  233  232  231  230  229  228  227  226  225  224  Older
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230208 21:10:45